Peel Hunt restated their buy rating on shares of PureTech Health (LON:PRTC) in a report published on Wednesday morning, ThisIsMoney.Co.Uk reports. Peel Hunt currently has a GBX 380 ($4.97) target price on the stock, up from their previous target price of GBX 344 ($4.49).
PRTC has been the subject of a number of other research reports. Peel Hunt restated a buy rating and set a GBX 650 ($8.49) price target on shares of JD Sports Fashion in a research note on Wednesday, July 3rd. Liberum Capital raised their price target on shares of Moneysupermarket.Com Group from GBX 520 ($6.79) and gave the stock a buy rating in a research note on Thursday, July 11th. Finally, Jefferies Financial Group raised their price target on shares of PureTech Health from GBX 280 ($3.66) to GBX 340 ($4.44) and gave the stock a buy rating in a research note on Friday, July 5th.
Shares of PRTC opened at GBX 266 ($3.48) on Wednesday. The company has a market capitalization of $751.43 million and a PE ratio of -16.63. The company has a current ratio of 0.98, a quick ratio of 0.95 and a debt-to-equity ratio of 7.19. PureTech Health has a 12 month low of GBX 135 ($1.76) and a 12 month high of GBX 253.10 ($3.31). The business’s 50-day simple moving average is GBX 230.68.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Further Reading: What is the float in trading stocks?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.